Spero Therapeutics Reports Strong Q1 Financials, Extends Cash Runway into 2028, and Resolves SEC Investigation

summarizeSummary

Spero Therapeutics announced strong Q1 2026 financial results, including a reduced net loss and increased cash, extending its runway into 2028, while also confirming the resolution of an SEC investigation and the PDUFA date for tebipenem HBr.

check_boxKey Events

• Improved Q1 Financial Performance

  The company reported a net loss of $7.2 million for Q1 2026, a significant improvement compared to a net loss of $13.9 million in Q1 2025. Cash and cash equivalents increased to $56.1 million as of March 31, 2026, up from $40.3 million at December 31, 2025.

• Extended Cash Runway

  Existing cash and cash equivalents are now projected to fund operating expenses and capital expenditure requirements into 2028, providing a longer financial runway.

• SEC Investigation Concluded

  The SEC concluded its investigation into the company on January 20, 2026, with no enforcement action recommended against Spero Therapeutics. Former executives settled related charges.

• GSK Milestone Payment Received

  Spero Therapeutics received a $25.0 million milestone payment in February 2026 from GSK following the NDA resubmission for tebipenem HBr to the FDA.

auto_awesomeAnalysis

Spero Therapeutics reported significantly improved first-quarter financial results, reducing its net loss and substantially increasing its cash position, primarily due to a $25.0 million milestone payment from GSK. This has extended the company's cash runway into 2028, providing crucial financial stability for a clinical-stage biotech. The conclusion of the SEC investigation with no enforcement action against the company removes a major regulatory overhang. The company also confirmed the June 18, 2026 PDUFA date for its lead asset, tebipenem HBr, reinforcing its strategic focus on this program following the termination of other earlier-stage candidates.